A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times.

BACKGROUND The study objective of this pilot study was to determine the lung delivery of HFA-134a-beclomethasone dipropionate (HFA-BDP; QVAR™) and CFC-beclomethasone dipropionate (CFC-BDP; Becloforte™) with and without the add-on spacers, Aerochamber™, and Volumatic™. The smaller particles of HFA-BDP were presumed to produce greater lung deposition using spacers, with and without a delay [i.e., metered dose inhaler (MDI) actuation into the spacer and subsequent inhalation 0 and 2 sec later], compared with the larger particles of CFC-BDP. The study included a comparison of breathhold effects (i.e., 1 and 10-sec breatholds) on lung deposition. METHODS The study was an open-label design and utilized healthy subjects (n = 12 males). Each arm of the study contained three subjects; thus, outcomes were not powered to assess statistical significance. HFA-BDP and CFC-BDP were radiolabeled with technetium-99m and delivered to subjects. RESULTS Results showed that the small particle HFA-BDP lung deposition averaged 52% and was not affected by the use of Aerochamber with or without a spacer delay. The oropharyngeal deposition of HFA-BDP was reduced from approximately 28% to 4% with the Aerochamber. Lung deposition with the large particle CFC-BDP was 3-7% and generally decreased with Aerochamber or Volumatic. A 2-sec time delay between actuation and breath plus the spacer reduced lung deposition slightly but reduced oropharygeal deposition substantially (84% down to 3-20%) using the Aerochamber or Volumatic with and without a spacer delay. HFA-BDP lung deposition was dependent on the breathhold. Lung deposition with HFA-BDP was reduced by 16% with a 1-sec versus 10-sec breathhold. The difference was measured in the increased exhaled fraction, confirming that smaller particles need time to deposit and are exhaled if there is a reduced breathhold. The large particle CFC-BDP lung deposition was not affected by breathhold. CONCLUSIONS The use of Aerochamber or Volumatic spacers with HFA-BDP did not alter lung deposition but it did reduce oropharyngeal deposition. However, HFA-BDP displayed reduced oropharyngeal deposition without a spacer.

[1]  B. Lipworth,et al.  Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. , 1996, Thorax.

[2]  N. Sheahan,et al.  Deposition of pressurised aerosols in the human respiratory tract. , 1981, Thorax.

[3]  C. Leach,et al.  Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. , 1998, The European respiratory journal.

[4]  P. N. Souëf,et al.  Distribution of technetium-99m-labelled QVARTM delivered using an AutohalerTM device in children , 2003, European Respiratory Journal.

[5]  A. Drollmann,et al.  Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[6]  C. Leach,et al.  Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone : a cross-over study in healthy volunteers. , 2002, Chest.

[7]  W. Busse,et al.  Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. , 1999, The Journal of allergy and clinical immunology.

[8]  H. Matthys,et al.  New method for easy labeling of beta-2-agonists in the metered dose inhaler with technetium 99m. , 1988, Respiration; international review of thoracic diseases.

[9]  D. J. Velasquez,et al.  A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. , 1999, International journal of pharmaceutics.

[10]  N. Shaw,et al.  Inhaled beclomethasone and oral candidiasis. , 1986, Archives of disease in childhood.

[11]  J. L. Rau,et al.  Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. , 2005, Chest.

[12]  Bruce K Rubin,et al.  Optimizing aerosol delivery by pressurized metered-dose inhalers. , 2005, Respiratory care.

[13]  P. Barry,et al.  The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. , 1995, British journal of clinical pharmacology.

[14]  C. Leach,et al.  Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[15]  P. N. Souëf,et al.  Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children , 2006, European Respiratory Journal.